By redirecting inhibitory signals such as PD-L1 and TGF-β through synthetic receptors with activating domains (e.g., CD28, 4-1BB), CSRs could enhance the persistence and function of ILCs within immunosuppressive tumor microenvironments (TMEs). The gene discussed is CD28; the disease is neoplasm.